Multicystic peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC)

In Vivo. 2008 Jan-Feb;22(1):153-7.

Abstract

Background: Multicystic peritoneal mesothelioma (MPM) is an extremely uncommon lesion with uncertain malignant potential. Multiple recurrences after surgical interventions and transition to aggressive malignancies have been reported. Here, we review our experience with cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of MPM.

Patients and methods: Five women with MPM underwent 6 procedures of cytoreduction and close-abdomen HIPEC with cisplatin and doxorubicin. Three patients had recurrent disease after 1, 2 and 4 previous debulkings, respectively.

Results: Optimal cytoreduction (residual tumor nodules < or =2.5 mm) was performed in all the procedures. One grade 4 postoperative complication (NCI/CTCAE v.3.0) and no operative mortality occurred. Median follow-up was 31 months (range 3-102). MPM recurred in two patients: one is presently disease-free after a second cytoreduction with HIPEC and the other is alive with minimal stable disease.

Conclusion: Definitive eradication by means of cytoreduction and HIPEC seems a safe and effective therapeutic option for MPM.

MeSH terms

  • Adult
  • Chemotherapy, Cancer, Regional Perfusion*
  • Combined Modality Therapy
  • Disease-Free Survival
  • Female
  • Humans
  • Hyperthermia, Induced*
  • Mesothelioma, Cystic / mortality
  • Mesothelioma, Cystic / pathology
  • Mesothelioma, Cystic / therapy*
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Neoplasm, Residual / pathology
  • Neoplasm, Residual / therapy
  • Peritoneal Neoplasms / mortality
  • Peritoneal Neoplasms / pathology
  • Peritoneal Neoplasms / therapy*
  • Reoperation
  • Survival Rate
  • Treatment Outcome